{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "Fort Lauderdale",
      "state": "FL",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "73698",
      "recalling_firm": "Invisiblu International LLC",
      "address_1": "620 SE 13th St",
      "address_2": "N/A",
      "postal_code": "33316-2023",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "Nationwide and Brazil.",
      "recall_number": "D-0910-2016",
      "product_description": "LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle,  Manufactured for Continuum Labs, Fort Lauderdale, FL",
      "product_quantity": "3,319 bottles",
      "reason_for_recall": "Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033",
      "recall_initiation_date": "20160331",
      "center_classification_date": "20160527",
      "report_date": "20160608",
      "code_info": "Lot # 21511166, Exp 11/18"
    }
  ]
}